Peng Zou, PhD

Clinical Pharmacologist
Daiichi Sankyo Inc.
Boyds, Maryland

Dr Peng Zou is a Director of Clinical Pharmacology in the Quantitative Clinical Pharmacology Department of Daiichi Sankyo Inc. He serves as a clinical pharmacology representative for multiple clinical development programs in the Specialty Medicines portfolio. Prior to joining Daiichi Sankyo, Peng was employed by the Food & Drug Administration (FDA) in the Office of Clinical Pharmacology (OCP). While in that role, he reviewed the clinical pharmacology sections over 250 NDA, BLA and IND submissions. Prior to working in the OCP, Peng was in the Office of Pharmaceutical Quality at the FDA, where he reviewed the chemistry, manufacturing, and controls (CMC) sections of more than 70 ANDAs and DMFs. During his career at the FDA, he also served as the principal investigator for multiple research projects funded by FDA intramural grants such as Critical Path, PHCE, RSR and CORES. During his career in Clinical Pharmacology, he has been a contributor to the scientific community, with approximately 50 journal and 40 poster publications, 20 invited oral presentations at national and international conferences and webinars, as well as being named on two patents.

Disclosure information not submitted.

Presentation(s):

• An Unaddressed Scientific Need: Predicting Human Bioavailability of Subcutaneously Administered Fc-Fusion Proteins and Monoclonal Antibodies

  Monday, October 17, 2022
  9:00 AM – 9:30 AM ET

• First-in-Patient Dose Prediction for Adeno-Associated Virus-Mediated Hemophilia Gene Therapy

  Tuesday, October 18, 2022
  3:15 PM – 3:30 PM ET